European reg for children’s meds
This article was originally published in The Tan Sheet
The European Commission reached an agreement on an updated regulatory approach for pediatric medicines, according to the UK's Medicines & Healthcare products Regulatory Agency (MHRA) June 1. "The overall policy objective is to improve the health of the children of Europe by increasing the research, development and authorization of medicines for use in children," the proposal for the regulation states. Specific objectives of the measure include increasing development for children's medicines, improving the quality of research for children's medicinal products and ensuring that all medicines used for children are appropriate for pediatric use. MHRA expects that the proposed regulation will be passed into law by the end of 2006...
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.